Item request has been placed!
×
Item request cannot be made.
×
Processing Request
High L-Type Amino Acid Transporter 1 Levels Are Associated with Chemotherapeutic Resistance in Gastric Cancer Patients.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Source:
Publisher: Karger Country of Publication: Switzerland NLM ID: 0135054 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1423-0232 (Electronic) Linking ISSN: 00302414 NLM ISO Abbreviation: Oncology Subsets: MEDLINE
- Publication Information:
Original Publication: Basel, New York, Karger.
- Subject Terms:
- Abstract:
Introduction: We investigated whether the expression of L-type amino acid transporter 1 (LAT-1) in clinical gastric cancer (GC) patients could predict patient therapeutic response to postoperative adjuvant chemotherapy.
Methods: Immunohistochemistry was used to investigate LAT-1, CD98, and phosphorylated-mammalian target of rapamycin (p-mTOR) expression in 111 GC patients. To clarify whether LAT-1 influences the therapeutic effects of chemotherapy, the correlation between disease-free survival rates and LAT-1 was determined in 2 groups: 59 patients who did not undergo postoperative adjuvant chemotherapy and 52 patients who did undergo postoperative adjuvant chemotherapy.
Results: LAT-1 was significantly correlated with CD98 and p-mTOR expressions. We did not find any statistically significant correlation between LAT-1 and recurrence in the nontreated group. In contrast, a significant association was found between LAT-1 expression and disease-free survival in the chemotherapy group. Moreover, multivariate regression analysis demonstrated that LAT-1 was an independent predictor of disease-free survival in the postoperative adjuvant chemotherapy group (p = 0.012).
Conclusion: Our findings demonstrate that LAT-1 is a useful predictive marker for a successful postoperative adjuvant chemotherapy treatment.
(© 2021 S. Karger AG, Basel.)
- Contributed Indexing:
Keywords: Chemotherapeutic resistance; Chemotherapy; Gastric cancer; L-type amino acid transporter 1; Mammalian target of rapamycin
- Accession Number:
0 (Antimetabolites, Antineoplastic)
0 (Biomarkers, Tumor)
0 (Drug Combinations)
0 (Fusion Regulatory Protein-1)
0 (Large Neutral Amino Acid-Transporter 1)
0 (SLC7A5 protein, human)
150863-82-4 (S 1 (combination))
1548R74NSZ (Tegafur)
5VT6420TIG (Oxonic Acid)
EC 2.7.1.1 (MTOR protein, human)
EC 2.7.11.1 (TOR Serine-Threonine Kinases)
U3P01618RT (Fluorouracil)
- Publication Date:
Date Created: 20210815 Date Completed: 20211112 Latest Revision: 20211204
- Publication Date:
20240829
- Accession Number:
10.1159/000517371
- Accession Number:
34392246
No Comments.